Myxoinflammatory fibroblastic sarcoma: A rare case affecting only the dermis

Myxoinflammatory fibroblastic sarcoma

“…This case, like the majority of these tumours demonstrate strong immunoreactivity for vimentin and D2‐40 1,3 . However, the absence of distinctive immunohistochemical markers makes it difficult to differentiate them from other similar soft tissue tumours which resemble MIFS in terms of clinical presentation and histopathological findings, including hemosiderotic fibrolipomatous tumour and pleomorphic hyalinizing angiectatic tumour 4 …”

“…1,3 However, the absence of distinctive immunohistochemical markers makes it difficult to differentiate them from other similar soft tissue tumours which resemble MIFS in terms of clinical presentation and histopathological findings, including hemosiderotic fibrolipomatous tumour and pleomorphic hyalinizing angiectatic tumour. 4 Due to MIFS high local recurrence rate and associated morbidity, complete margin-negative excision is the most evidenced approach to reduce this rate. 5,6 There might be a role of pre-operative radiation therapy in deep and high-grade extremity soft tissue sarcomas.…”

Myxoinflammatory fibroblastic sarcoma of the liver: Case report and literature review

“…[13,14] However, the local recurrence rate is relatively high, ranging from 22% to 67%, and recurrence typically occurs 3 to 5 years after the first operation. [15,16] Because the clinical manifestations of MIFS are similar to benign lesions, such as tenosynovitis, ganglion cysts, tenon sheath fibromas, giant cell tumors of the tenon sheath, or fibromatosis, physicians typically do not provide adequate initial treatment, making it easy to relapse after surgery. At present, many researchers are analyzing the cytogenetic characteristics of MIFS.…”